Insights

Growth Funding VerImmune has secured pre-Series A funding and received a $4.5M financing round in 2024, plus a $500K MEIF investment in 2025, indicating active investor support and potential capital for scaling partnerships, contract research, or collaboration programs in ViP platform development.

Platform Commercialization The ViP platform delivery technology and lead candidate VERI-101 signal a focus on virus-inspired cancer therapies; explore opportunities to license platform capabilities, co-development, or sponsor-funded studies with biopharma partners seeking novel immuno-oncology approaches.

Clinical Pipeline Current emphasis on melanoma and other cancers with advancement toward clinical trials suggests demand for CRO services, GMP manufacturing support, CMC optimization, and regulatory strategy partnerships to accelerate translational progress.

Leadership & Talent Key hires at the CMC leadership level and a growing team indicate a maturing organization; target engagement for manufacturing, analytical development, and regulatory affairs collaborations, as well as potential supplier or advisory partnerships.

Regional Focus Headquartered in Maryland with local investment activity; there is a geographic opportunity to align with regional biotech ecosystems, state-funded programs, and local contract manufacturers or service providers for rapid-supply and regulatory-compliant manufacturing.

Similar companies to VerImmune

VerImmune Tech Stack

VerImmune uses 8 technology products and services including Open Graph, Squarespace, Microsoft Azure DNS, and more. Explore VerImmune's tech stack below.

Media & News

VerImmune's Email Address Formats

VerImmune uses at least 3 email formats:
VerImmune Email FormatsExamplePercentage
First.Last@verimmune.comJohn.Doe@verimmune.com
89%
FLast@verimmune.comJDoe@verimmune.com
5%
Last.First@verimmune.comDoe.John@verimmune.com
6%

Frequently Asked Questions

What is VerImmune's official website and social media links?

Minus sign iconPlus sign icon
VerImmune's official website is verimmune.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does VerImmune generate?

Minus sign iconPlus sign icon
As of August 2026, VerImmune's annual revenue is estimated to be $1M - $10M.

What is VerImmune's SIC code and NAICS code?

Minus sign iconPlus sign icon
VerImmune's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does VerImmune have currently?

Minus sign iconPlus sign icon
As of August 2026, VerImmune has approximately 13 employees across 2 continents, including North America and Asia. Key team members include Head Of Cmc / Cmc Advisor: S. A., Business Development And Operations Manager: K. W. and Member Board Of Directors: H. S. Explore VerImmune's employee directory with LeadIQ.

What industry does VerImmune belong to?

Minus sign iconPlus sign icon
VerImmune operates in the Biotechnology Research industry.

What technology does VerImmune use?

Minus sign iconPlus sign icon
VerImmune's tech stack includes Open Graph, Squarespace, Microsoft Azure DNS, Squarespace Commerce, Microsoft 365, Azure Active Directory, Choices and HSTS.

What is VerImmune's email format?

Minus sign iconPlus sign icon
VerImmune's email format typically follows the pattern of First.Last@verimmune.com. Find more VerImmune email formats with LeadIQ.

How much funding has VerImmune raised to date?

Minus sign iconPlus sign icon
As of August 2026, VerImmune has raised $11M in funding. The last funding round occurred on Sep 23, 2024 for $4.5M.

When was VerImmune founded?

Minus sign iconPlus sign icon
VerImmune was founded in 2019.
VerImmune logo

VerImmune

Biotechnology ResearchMaryland, United States11-50 Employees

VerImmune is a biotechnology research company based in Bethesda, Maryland, that is developing an approach called Anti-tumor Immune Redirection (AIR). AIR aims to redirect pre-existing immune memory generated by childhood vaccination or prior infections to combat solid tumors, offering a first-in-class strategy in cancer therapy. The company operates within the immuno-oncology landscape, focusing on therapies that leverage the patient’s existing immune history to target cancer, and positioned as a small-to-mid sized player in this sector. VerImmune is led by a relatively small team and has undertaken leadership changes and early-stage development activities, with recent organizational moves including appointments to strengthen its chemistry, manufacturing, and controls capabilities. The organization is headquartered in Bethesda, Maryland, and has a corporate focus on translating its AIR concept into clinical applications for solid tumors.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
11-50

Section iconFunding & Financials

  • $11M

    VerImmune has raised a total of $11M of funding over 4 rounds. Their latest funding round was raised on Sep 23, 2024 in the amount of $4.5M as a Seed.

  • $1M - $10M

    VerImmune's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.